Decitabine limits escape from MEK inhibition in uveal melanoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metastatic uveal melanoma (MUM) has limited treatment options.
• MEK inhibitors (MEKi) show initial anti-proliferative activity in MUM but responses are transient.

Purpose of the Study:

• To evaluate the efficacy of combining MEKi trametinib with epigenetic drugs in uveal melanoma.
• To investigate the underlying mechanisms of the combination therapy.

Main Methods:

• Cell viability, colony formation, and 3D organoid assays were used to assess anti-proliferative activity.
• RNA-Seq analysis was performed to identify affected gene expression pathways.
• In vivo studies utilized uveal melanoma xenografts to evaluate therapeutic effects.

Main Results:

• The DNA methyltransferase inhibitor (DNMTi) decitabine significantly enhanced trametinib's anti-proliferative effects.
• The combination therapy modulated genes involved in cell cycle checkpoints, cell survival, and mitosis.
• In vivo, the DNMTi-MEKi combination demonstrated superior suppression of uveal melanoma xenograft growth compared to monotherapy.

Conclusions:

• DNMT inhibitors can enhance the therapeutic activity of MEK inhibitors in uveal melanoma.
• The combination therapy offers a promising strategy for overcoming resistance to MEKi in uveal melanoma.